Bragar Eagel & Squire, P.C. is investigating potential claims against Alnylam Pharmaceuticals, Inc. on behalf of stockholders over possible federal securities-law violations and other unlawful business practices. Alnylam reported its second-quarter 2026 results on July 30, 2026, and lowered full-year TTR product sales guidance after assessing the initial launch phase in the evolving ATTR-CM market. The company cited normalized growth in second-line volume after pent-up demand from patients waiting for a new therapy had been met. Alnylam reduced projected total TTR net product revenues by approximately $200 million, sending its shares down as much as $81.25, or 28.35%, in intraday trading that day. The firm is inviting investors who purchased or acquired Alnylam shares, suffered losses, or have relevant information to contact its attorneys about their rights and potential claims.